Scarica l'app Stockscreener
10.61
1.58%
-0.17
Pre-mercato:
10.80
0.19
+1.79%
Arvinas Inc Borsa (ARVN) Ultime notizie
Pfizer, Arvinas breast cancer therapy approved by the FDA - MSN
What Arvinas says on May 12: Q1 results and corporate update - Stock Titan
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 - Caledonian Record
ARVN Maintained by Citigroup -- Price Target Raised to $24 - GuruFocus
Arvinas/Pfizer To Announce Veppanu Commercialization Partner In Weeks - Citeline News & Insights
Arvinas (NASDAQ:ARVN) Shares Gap DownShould You Sell? - MarketBeat
Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy - Benzinga
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations - BioSpace
Protein degraders gain speed as Arvinas scores landmark approval - Pharma Voice
FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data - BioSpace
Hussman Strategic Advisors Inc. Buys New Shares in Arvinas, Inc. $ARVN - MarketBeat
Arvinas’ Veppanu, First Breast Cancer Drug of Its Kind Approved by FDA, Seeks Commercialization Partner - geneonline.com
How The Arvinas (ARVN) Story Is Shifting With Vepdeg And ARV-102 Milestones - Yahoo Finance
FDA approves Pfizer-Arvinas breast cancer pill Veppanu for advanced cases - Investing.com
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
FDA Approves Pfizer and Arvinas Breast Cancer Drug - Intellectia AI
US FDA approves Pfizer, Arvinas' breast cancer drug - Reuters
Truist Financial Maintains Arvinas(ARVN.US) With Hold Rating, Announces Target Price $10 - Moomoo
FDA Approves Vepdegestrant for Advanced Breast Cancer Treatment - GuruFocus
Arvinas (NASDAQ:ARVN) Shares Up 9.9%What's Next? - MarketBeat
BTIG reiterates Arvinas stock rating on breast cancer drug approval By Investing.com - Investing.com South Africa
BTIG reiterates Arvinas stock rating on breast cancer drug approval - Investing.com
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA - BioPharma Dive
FDA approves first PROTAC drug for ESR1-mutated breast cancer - Stock Titan
VEPPANU Receives FDA Approval, Pioneering PROTAC Therapy Era - Intellectia AI
Arvinas (ARVN) Secures Early Approval for Vepdeg in Breast Cance - GuruFocus
Arvinas shares gain as FDA approves breast cancer drug Veppanu - Investing.com
US FDA approves Pfizer, Arvinas’ breast cancer drug - WKZO
Arvinas Gains First FDA Approval for Breast Cancer Drug - TipRanks
Pfizer, Arvinas breast cancer drug approved (update) (PFE:NYSE) - Seeking Alpha
Arvinas shares gain as FDA approves breast cancer drug Veppanu By Investing.com - Investing.com Canada
FDA approves Arvinas’ vepdegestrant for breast cancer treatment By Investing.com - Investing.com Canada
Arvinas announces FDA approval of Veppanu for treatment of ESR1m, ER+/HER2- advanced breast cancer - marketscreener.com
FDA clears Arvinas (NASDAQ: ARVN) VEPPANU for advanced breast cancer - Stock Titan
FDA approves Arvinas’ vepdegestrant for breast cancer treatment - Investing.com UK
Arvinas and Pfizer Announce FDA Approval of VEPPANU™ as First-Ever PROTAC for Advanced Breast Cancer Treatment - Quiver Quantitative
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) - GlobeNewswire
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach - MSN
(ARVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
[ARS] ARVINAS, INC. SEC Filing - Stock Titan
Arvinas (NASDAQ: ARVN) details 2026 virtual meeting, director and pay votes - Stock Titan
Arvinas (NASDAQ:ARVN) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
Vanguard Portfolio Management owns 3.92M Arvinas shares (ARVN) - Stock Titan
Arvinas CEO John Houston to retire - MSN
Arvinas stock slides after eliminating trials, reducing workforce - MSN
Arvinas, Inc. (ARVN) reports Q4 loss, misses revenue estimates - MSN
Arvinas announces $100M share repurchase program - MSN
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - MSN
Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN
Arvinas earns relative strength rating upgrade; hits key benchmark - MSN
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):